LLY

As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.

South Korea has been the second most important contributor to the growth of Asian innovation in recent years, outperforming Japan in several areas. Read more here.

The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.

Evan Seigerman, BMO Capital Markets senior pharma analyst, joins 'Squawk Box' to discuss the state of the pharma sector, latest GLP-1 developments, weight-loss drug market competition, and more.

The highest dose of a single injection reduced cholesterol levels by 62% in patients, according to Eli Lilly's recently published study.

Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk.

Eli Lilly's fair value estimate has shifted slightly from US$1,209.21 to US$1,211.03 per share, a small move that still reflects meaningful debate around what is already priced into the stock. Much of the recent analyst discussion links this updated target range to retatrutide Phase 3 data, with bulls highlighting GLP-1 leadership and bears questioning how much future obesity growth is already embedded. As you read on, you will see how these competing views shape the evolving narrative around...